站在转化医学的十字路口，这项研究带来的启示远超实验数据本身。首先，它验证了表观遗传调控在抗癌药物开发中的战略地位；其次，揭示了多靶点协同作用的可能性；更重要的是为中药现代化提供了分子层面的理论支撑。对于药企研发部门，建议优先布局三重方向：建立标准化提取工艺、探索与现有化疗方案的协同效应、开发靶向递送系统。监管部门则需要加快建立天然抗癌成分的质量控制体系，而临床机构应当着手设计早期临床试验方案。

This valuable study investigates the immune system's role in pre-eclampsia. The authors map the immune cell landscape of the human placenta and find an increase in macrophages and Th17 cells in ...

这种非线性增长模式提示，有效浓度区间的把握可能成为临床应用的关键。从分子生物学角度解析，该成分通过重构p53-S100A4基因表达网络，实现了对癌细胞增殖的双向调控。 深入探究基因调控网络，p53基因的激活与S100A4基因的抑制构成动态平衡系统。实验数据 ...

S100A4 is a Ca 2+-binding protein involved in multiple chronic inflammatory and neoplastic conditions. This review focuses on recent advances in the understanding of S100A4 function in immune cells, ...

Methods: In the present study, we performed the complex analysis of mRNA and protein expression of crucial regulators of tumor angiogenesis and tumor progression, expressed by tumor-associated ...